Drug Profile
Research programme: gene therapy - 4D Molecular Therapeutics/Foundation Fighting Blindness
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator 4D Molecular Therapeutics
- Developer 4D Molecular Therapeutics; Foundation Fighting Blindness
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Retinal-disorders in USA (Intravitreous)
- 24 Jul 2017 Early research in Retinal disorders in USA (Intravitreous)
- 24 Jul 2017 4D Molecular Therapeutics and Foundation Fighting Blindness enters into collaboration to develop AAV-based gene therapy in USA for Retinal diseases